前列腺癌治疗分配和风险评估的预测性特征

Oncoscience Pub Date : 2015-11-20 DOI:10.18632/ONCOSCIENCE.271

D. Bonci, R. De Maria

{"title":"前列腺癌治疗分配和风险评估的预测性特征","authors":"D. Bonci, R. De Maria","doi":"10.18632/ONCOSCIENCE.271","DOIUrl":null,"url":null,"abstract":"Prostate cancer remains the second leading cause of death in men. It is imperative to improve patient management in identifying bio-markers for personalized treatment. We demonstrated miR-15/miR-16 loss and miR-21 up-regulation and deregulation of their target genes, which represent a promising signature for ameliorating therapy assignment and risk assessment in prostate cancer.","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"8 1","pages":"920 - 923"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"A predictive signature for therapy assignment and risk assessment in prostate cancer\",\"authors\":\"D. Bonci, R. De Maria\",\"doi\":\"10.18632/ONCOSCIENCE.271\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Prostate cancer remains the second leading cause of death in men. It is imperative to improve patient management in identifying bio-markers for personalized treatment. We demonstrated miR-15/miR-16 loss and miR-21 up-regulation and deregulation of their target genes, which represent a promising signature for ameliorating therapy assignment and risk assessment in prostate cancer.\",\"PeriodicalId\":94164,\"journal\":{\"name\":\"Oncoscience\",\"volume\":\"8 1\",\"pages\":\"920 - 923\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18632/ONCOSCIENCE.271\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/ONCOSCIENCE.271","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

摘要

前列腺癌仍然是男性死亡的第二大原因。提高患者管理水平，识别生物标志物，实现个性化治疗势在必行。我们证明了miR-15/miR-16缺失和miR-21靶基因的上调和解除调控，这代表了改善前列腺癌治疗分配和风险评估的有希望的标志。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A predictive signature for therapy assignment and risk assessment in prostate cancer

Prostate cancer remains the second leading cause of death in men. It is imperative to improve patient management in identifying bio-markers for personalized treatment. We demonstrated miR-15/miR-16 loss and miR-21 up-regulation and deregulation of their target genes, which represent a promising signature for ameliorating therapy assignment and risk assessment in prostate cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoscience

自引率

0.00%

发文量